Cantor Fitzgerald analyst Louise Chen said based on her discussions with doctors in attendance at the AHA meeting, she believes the physician community remains "very receptive" to the REDUCE-IT data and noted that "no one" she spoke with seemed concerned about label limitations for Vascepa. Chen also noted that an audience poll during one Continuing Medical Education program showed that nearly all of the physicians in the audience plan to prescribe EPA 4g/day for patients with triglycerides between 200-500 mg/dL. Chen maintains an Overweight rating and $35 price target on Amarin shares.